Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Breast Cancer × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 128 Melanoma 89 Squamous Cell Carcinoma of Head and Neck 87 Breast Neoplasms 70 Triple Negative Breast Neoplasms 63 Parkinson Disease 4, Autosomal Dominant Lewy Body 44 Head and Neck Neoplasms 44 Lung Neoplasms 38 Neoplasm Metastasis 37 Colorectal Neoplasms 37 Ovarian Neoplasms 36 Neoplasms 35 Stomach Neoplasms 34 Carcinoma, Renal Cell 34 Carcinoma, Transitional Cell 31 Pancreatic Neoplasms 29 Urinary Bladder Neoplasms 27 Carcinoma, Hepatocellular 27 Hodgkin Disease 21 Uterine Cervical Neoplasms 20 Recurrence 20 Endometrial Neoplasms 19 Prostatic Neoplasms 18 Esophageal Neoplasms 18 Sarcoma 17 Brain Neoplasms 16 Glioblastoma 15 Fallopian Tube Neoplasms 15 Esophageal Squamous Cell Carcinoma 15 Carcinoma, Squamous Cell 14

Interventions

Fulvestrant 8 olaparib 4 Capecitabine 4 pyrotinib 3 Docetaxel 3 Vinorelbine 2 Trastuzumab 2 Letrozole 2 Alpelisib 2 vandetanib 1 trastuzumab deruxtecan 1 talazoparib 1 sacituzumab govitecan 1 pembrolizumab 1 neratinib 1 liposomal doxorubicin 1 exemestane 1 eribulin 1 dalpiciclib 1 ceralasertib 1 cediranib 1 capivasertib 1 abemaciclib 1 Tablets 1 Moxifloxacin 1 Injections 1 Goserelin 1 Gemcitabine 1 Everolimus 1 Dasatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03025880 2023-04-03

PANGEA

Spanish Breast Cancer Research Group

Phase 2 Completed

36 enrolled 28 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡